

Bristol-Myers Squibb Company (BMJ)

Healthcare / Drug Manufacturers - General · New York Stock Exchange

Generated: 2026-Oct-18 · Market data through: 2026-10-16

LAST CLOSE \$59.75 2026-10-16	MARKET CAP \$122.1B VOLUME 12.8M	52-WK HIGH \$68.64 52-WK LOW \$42.52	TRAILING PE 13.2 P/S 2.48	GROSS MARGIN 70.2% NET MARGIN 18.9%	ROE 47% ROIC 15%	PIOTROSKI 7/9 ALTMAN Z 2.7	1-YR RETURN +43.8% 5-YR RETURN +65.5%
--	---	---	--	--	---	---	--

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

SECTOR Healthcare INDUSTRY Drug Manufacturers - General EXCHANGE NYSE MARKET CAP \$122.1B EMPLOYEES 32,500 (SEC-filed) CEO Christopher Boerner
IPO 1972-06-01 COUNTRY US
Route 206 & Province Line Road, Princeton, NJ 08543 · Tel 609 252 4621 · bms.com

1 INSIDERSTREET SCORE

INSIDERSTREET SCORE

68 / 100

Street mean **\$65.54** (13 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNAL


ROUTINE SELLING — LOW SIGNAL

\$2M sold / 6 mo, zero open-market buys

2 PRICE AND VOLUME

adjusted close, prod data layer

1 Year vs S&P 500 · **BMJ +43.8%** · **S&P 500 +15.9%** · spread **+28.0pp**



7 Years vs S&P 500 · **BMJ +65.5%** · **S&P 500 +189.9%** · spread **-124.4pp**



Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

3 INSIDERSTREET SCORE

live IS factor model

INSIDERSTREET
SCORE
68
OF 100


Score Breakdown

Profitability	89/100
Growth	63/100
Momentum	87/100
Quality	80/100
Earnings Quality	71/100
Balance Sheet	53/100
Value	67/100
Risk (safety)	65/100
Overall	67.7/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is **not** the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.


Peer Comparison — IS Score

SYMBOL	IS SCORE
PFE	46
GILD	44
AMGN	67
AZN	71
NVS	65
MRK	49
BMY	68



4 TWO READINGS

business vs price



These two disagree — business quality 68, price structure 34 out of 100, so the business reads better than the price does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

5 WHAT WOULD CHANGE OUR MIND falsifiable - check us next quarter

TRIGGER	WHERE IT STANDS NOW	WHAT IT WOULD MEAN
IS Score reaches 75 and holds two consecutive quarters	now 67.7	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 67 → 62 → 66 → 68	the direction matters more than the level
Technical vote share back above 50%	now 18%	price structure no longer broken
Institutional holder count rises two quarters running	peak 2,545 → now 2,534	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.


6 SMART MONEY CONFLUENCE EDGE · disclosure sources

SITE CONVERGENCE SCORE 2 of 4 top 13% of 29,420 symbols	SOURCES ALIGNED — of 3 independent disclosures	CONGRESS (180D) 0 buys none disclosed	INSIDER BUYS (180D) 0 none disclosed
ETF FUNDS (30D) 1752 up / 1323 down net +429 funds	INSTITUTIONS ADDED (13F) -11 managers opening or increasing		

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

7 INSTITUTIONAL OWNERSHIP - 12-QUARTER TREND 13F · filed 45 days after quarter end

Institutions holding — 12 quarters



Peak 2,545 · latest 2,534 (-11 from peak).

QUARTER	HOLDERS	13F SHARES	VALUE	REPORTED OWN%
2026 Q2	2,534	1744.0M	\$96.5B	85.4%
2026 Q1	2,545	1619.8M	\$95.0B	79.3%
2025 Q4	2,466	1642.0M	\$86.4B	80.4%
2025 Q3	2,276	1587.8M	\$70.2B	77.8%
2025 Q2	2,305	1646.8M	\$75.6B	80.6%
2025 Q1	2,490	1634.4M	\$98.3B	80.0%
2024 Q4	2,496	1599.6M	\$88.9B	78.3%
2024 Q3	2,269	1549.1M	\$77.9B	75.9%
2024 Q2	2,161	1536.5M	\$62.5B	75.2%
2024 Q1	2,344	1562.3M	\$82.8B	76.5%
2023 Q4	2,371	1549.5M	\$78.6B	75.9%
2023 Q3	2,397	1570.8M	\$90.7B	76.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


8 INSIDER ACTIVITY live Form 4 data

INSIDER	ROLE	DATE	TYPE	SHARES	VALUE	POST-TXN OWNED
Gallman Cari	EVP, General Counsel	2026-10-02	EXERCISE	4,559	—	18,208
Gallman Cari	EVP, General Counsel	2026-10-02	TAX W/H	2,332	\$0.14M	15,876
Gallman Cari	EVP, General Counsel	2026-10-02	EXERCISE	4,559	—	0
Yale Phyllis R	director	2026-09-30	A-Award	561	—	45,980
Samuels Theodore R. li	director	2026-09-30	A-Award	821	—	71,859
Rice Derica W	director	2026-09-30	A-Award	621	—	42,085
Mcmullen Michael R.	director	2026-09-30	A-Award	561	—	17,051
Arduini Peter J	director	2026-09-30	A-Award	561	—	74,077

9 SELL DECOMPOSITION — ROUTINE VS. DISCRETIONARY EDGE

6-MO DECOMPOSITION (FORM 4)	TXNS	SHARES	VALUE	SIGNAL WEIGHT
S — Open-market sales	4	36,749	\$2.3M	Counted
M — Exercises (paired A/D)	41	299,974	\$1.1M	None — mechanics
F — Tax withholding	42	107,266	\$6.6M	None — compensation
P — Open-market purchases	0	0	\$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)



Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SIGNAL Routine Selling — Low Signal	OPEN-MARKET SELLS \$2.3M 4 txns / 6 mo	OPEN-MARKET BUYS \$0.0M 0 txns / 6 mo	CLUSTER None active 3+ insiders / 21 days
--	---	--	--

10 CONGRESSIONAL TRADING EDGE · STOCK Act

MEMBER	CHAMBER	TRADE	SIZE BAND	TRADED	DISCLOSED
Mike Kelly	House	SELL	\$15,001 - \$50,000	2026-05-07	2026-06-12
Mike Kelly	House	SELL	\$15,001 - \$50,000	2026-05-07	2026-06-12
Mike Kelly	House	SELL	\$15,001 - \$50,000	2026-05-06	2026-06-12
Tommy Tuberville	Senate	SELL	\$1,001 - \$15,000	2025-04-15	2026-08-05
Thomas Hawley Tuberville	Senate	SELL	\$1,001 - \$15,000	2025-04-15	2026-08-05
Tommy Tuberville	Senate	SELL	\$1,001 - \$15,000	2025-04-15	2025-05-15

HOUSE 12-MO 18 trades 5 purchases	SENATE 12-MO 0 trades None purchases	COVERAGE STOCK Act filings 30-45 day disclosure lag	
---	--	---	--

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

11 INSTITUTIONAL OWNERSHIP & 13F FLOW live 13F data


13F FILERS (LAST COMPLETE Q) 2,545	13F SHARES 1.62B 79.3% of shares out	NEW / CLOSED 271 / 148 positions, QoQ	INCREASED / REDUCED 1,065 / 880 positions, QoQ
PUT/CALL (13F) 0.92 option positions	FREE FLOAT 99.8% 2.04B sh		

2.8 · Largest Reporting 13F Managers

MANAGER	SHARES	VALUE
Artemis Investment Management Llp	2.8M	\$176M
Wealth Enhancement Advisory Servic	2.1M	\$104M
Fort Washington Investment Advisor	1.7M	\$107M
Douglas Lane & Associates, Llc	1.5M	\$94M
Fjarde Ap-Fonden /Fourth Swedish N	877,685	\$55M
Vontobel Holding Ltd.	767,237	\$48M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.


13F Filers Holding BMY — quarterly




2.9 · Top ETF & Fund Ownership

FUND	WEIGHT	POSITION
VITSX	0.2%	\$4.0B
VTI	0.2%	\$4.0B
VSMPX	0.2%	\$4.0B
VTSAX	0.2%	\$4.0B
SCHD	3.0%	\$3.4B
VOO	0.2%	\$3.3B

Institutional Put/Call — quarterly




12 SHORT VOLUME — DAILY, 60 SESSIONS EDGE · live FINRA feed



Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

LATEST SESSION 39.3% 2026-10-15	20-DAY AVG 44.2% 50-day 48.6%	TREND Falling 20d vs 50d	BY MARKET CENTER Q: 39% · N: 47% · B: 44% latest session
--	--	---------------------------------------	---

13 DARK POOL ACTIVITY EDGE · live ATS data



Where BMY Trades in the Dark


ATS VENUE (4-WK)	SHARES	AVG TRADE
Incr Intelligent Cross Llc	9.9M	83 sh
Ebxi Level Ats	6.5M	48 sh
Ubsa Ubs Ats	6.4M	68 sh
Mstx Ms Trajectory Cross (Ats-1)	6.0M	102 sh
Pure Purestream	4.0M	50 sh
Sgmt Sigma X2	3.9M	76 sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

14

REVENUE FLOW — FY2025

live segmentation + income data



Where a dollar of Bristol-Myers Squibb Company revenue goes. All values FY2025 filings, live.

15

GEOGRAPHIC REVENUE


live segmentation

REGION	REVENUE	SHARE
UNITED STATES	\$33.3B	97%
Other Region	\$1.1B	3%


16

MOAT & COMPETITIVE POSITION

LIVE MODEL · 56/100 NARROW



3.8 · Employees (SEC filings)



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


17 CORPORATE INFORMATION — KEY OFFICERS

32,500 employees

OFFICER	TITLE
Christopher S. Boerner	Chief Executive Officer & Chairman
David V. Elkins	Executive Vice President & Chief Financial Officer
Adam Lenkowsky	Executive Vice President & Chief Commercialization Officer
Greg Meyers	Executive Vice President and Chief Digital & Technology Officer


18 REVENUE & EPS — HISTORY AND ESTIMATES

live consensus



19 ESTIMATE VS. ACTUAL & SURPRISES

live data



20 REPORTED VS. CONSENSUS — FULL HISTORY

0 quarters · live data

BEAT RATE —% 0 of 0 quarters	CURRENT STREAK 0 longest 0	AVG EPS SURPRISE —% median —%	SURPRISE TREND — last 4 vs prior 4
------------------------------------	----------------------------------	-------------------------------------	--

PERIOD	EPS EST.	EPS ACTUAL	EPS SURPRISE	REV EST. (\$M)	REV ACTUAL (\$M)	REV SURPRISE
--------	----------	------------	--------------	----------------	------------------	--------------


Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE


NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INCOME TRENDS — 5 YEAR


live financials



Profit Margins (%)



Revenue by Segment — Stacked





Live segmentation data.

YoY Growth Heatmap — Income Lines

YOY GROWTH	FY21	FY22	FY23	FY24	FY25
Revenue	+9.1%	-0.5%	-2.5%	+7.3%	-0.2%
Gross profit	+23.3%	-1.0%	-4.3%	+8.2%	+18.8%
Operating income	+112.4%	-2.8%	-8.6%	+14.0%	+31.5%
Net income	-177.8%	-9.5%	+26.8%	-211.5%	-178.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

21 INCOME STATEMENT — FULL						live financials
\$B · FY ENDS	FY21	FY22	FY23	FY24	FY25	TREND
Revenue	46.4	46.2	45.0	48.3	48.2	
Cost of revenue	19.6	19.7	19.6	20.9	15.6	
Gross profit	26.8	26.5	25.4	27.4	32.6	
R&D expense	9.5	9.4	9.2	9.8	9.6	
SG&A expense	7.7	7.8	7.7	7.9	7.2	
Operating income	9.5	9.3	8.5	9.7	12.7	
EBITDA	20.1	19.2	19.4	3.2	14.5	
D&A	10.7	10.3	9.8	9.6	3.9	
Pretax income	8.1	7.7	8.4	-8.4	9.3	
Income tax	1.1	1.4	0.4	0.6	2.3	
Net income	7.0	6.3	8.0	-8.9	7.1	
Diluted EPS (\$)	3.12	2.95	3.86	-4.41	3.45	
Diluted shares (M)	2,245	2,146	2,078	2,027	2,041	



THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


Balance Sheet — Full

\$B	FY22	FY23	FY24	FY25	
Cash & equivalents	9.1	11.5	10.3	10.2	
ST investments	0.1	0.8	0.5	0.5	
Receivables (net)	13.9	15.3	14.4	14.5	
Total current assets	27.3	31.8	29.8	29.4	
PP&E (net)	7.5	8.0	8.4	9.1	
Goodwill + intangibles	57.5	48.7	45.4	40.9	
Total assets	96.8	95.2	92.6	90.0	
Accounts payable	3.0	3.3	3.6	3.6	
Short-term debt	4.3	3.1	2.0	2.3	
Deferred revenue	0.0	0.0	0.0	0.0	
Total current liabilities	21.9	22.3	23.8	23.4	
Long-term debt	35.1	36.7	47.6	42.9	
Total liabilities	65.7	65.7	76.2	71.5	
Shareholders' equity	31.1	29.5	16.4	18.5	


Cash Flow Statement — Full

\$B	FY22	FY23	FY24	FY25	
Net income	6.3	8.0	(8.9)	7.1	
D&A	10.3	9.8	9.6	4.0	
Stock-based compensation	0.5	0.5	0.5	0.6	
Working capital change	(2.2)	(1.9)	0.8	(0.5)	
Operating cash flow	13.1	13.9	15.2	14.2	
Capital expenditures	(1.1)	(1.2)	(1.2)	(1.3)	
Investing cash flow	(1.1)	(2.3)	(21.4)	(4.1)	
Buybacks	(8.0)	(5.2)	0.0	0.0	
Dividends paid	(4.6)	(4.7)	(4.9)	(5.0)	
Debt issuance / (repay)	(5.3)	0.5	10.1	(5.2)	
Financing cash flow	(17.0)	(9.4)	5.1	(10.3)	
Free cash flow	11.9	12.7	13.9	12.8	

Balance Sheet Structure (\$B)



Cash Generation vs Capex (\$B)



Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

22 EXPANDED RATIO ANALYSIS (I)

live ratio engine · profitability · valuation

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
PROFITABILITY							
ROE	19.0%	18.9%	26.5%	-39.1%	40.5%	47%	
ROA	6.1%	6.1%	8.4%	-9.5%	7.7%	10.6%	
ROIC	10.4%	12.3%	13.7%	12.5%	17.5%	15.4%	
Gross margin	57.7%	57.4%	56.3%	56.8%	67.6%	70.2%	
Operating margin	20.6%	20.1%	18.8%	20.0%	26.3%	28.1%	
Net margin	15.1%	13.7%	17.8%	-18.5%	14.6%	18.9%	
EBITDA margin	43.4%	41.6%	43.0%	6.6%	30.2%	34.2%	
FCF margin	32.8%	25.9%	28.1%	28.9%	26.7%	—	
VALUATION							
P/E	16.80	21.15	11.79	-12.27	15.43	13.2	
P/B	3.27	4.31	3.21	6.72	5.89	5.5	
P/S	2.53	2.90	2.10	2.27	2.26	2.48	
P/FCF	7.71	11.20	7.48	7.87	8.47	10.7	
EV/EBITDA	7.25	8.60	6.39	47.38	9.99	9.3	
EV/Revenue	3.14	3.58	2.75	3.11	3.01	3.2	
Earnings yield	6.0%	4.7%	8.5%	-8.2%	6.5%	7.61%	
FCF yield	13.0%	8.9%	13.4%	12.7%	11.8%	9.37%	

EXPANDED RATIO ANALYSIS (II)

leverage · solvency

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
LEVERAGE & SOLVENCY							
Current ratio	1.52	1.25	1.43	1.25	1.26	1.53	
Quick ratio	1.43	1.14	1.31	1.15	1.14	1.38	
Debt / equity	1.27	1.31	1.41	3.13	2.55	1.93	
Debt / assets	41.7%	42.1%	43.6%	55.3%	52.4%	49.2%	
Net debt / EBITDA	1.41	1.64	1.51	12.73	2.51	2.05	
Interest coverage	7.07	7.26	8.22	-3.30	7.08	—	

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EXPANDED RATIO ANALYSIS (III)							efficiency · growth · per-share · scores
RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
EFFICIENCY							
Asset turnover	0.41	0.45	0.47	0.51	0.53	0.56	
Receivables turnover	6.10	5.72	5.28	5.40	5.18	4.7	
DSO (days)	60	64	69	68	70	78	
DPO (days)	53	56	59	60	84	103	
Cash conversion cycle	46	49	57	53	48	43	
GROWTH (YoY)							
Revenue growth	9.1%	-0.5%	-2.5%	7.3%	-0.2%	—	
Net income growth	177.6%	-9.5%	26.8%	-211.5%	178.8%	—	
EPS growth	178.7%	-5.5%	32.5%	-211.3%	178.7%	—	
FCF growth	11.9%	-21.6%	5.9%	10.2%	-7.9%	—	
PER SHARE (\$)							
EPS (diluted, TTM)	3.15	2.98	3.95	-4.39	3.46	4.55	
Book value / share	16.20	14.62	14.48	8.02	9.05	10.93	
Revenue / share	20.90	21.73	22.14	23.71	23.61	24.09	
FCF / share	6.87	5.63	6.22	6.84	6.29	5.60	
Cash / share	7.76	4.36	6.04	5.33	5.23	5.42	
SHAREHOLDER RETURN & SCORES							
Buyback yield	5.4%	6.0%	5.5%	0.0%	0.0%	0.08%	
Altman Z-Score	2.10	2.44	2.21	1.46	2.18	2.7	
Piotroski F-Score	8	5	6	4	8	7/9	
Beneish M-Score	-2.77	-2.70	-2.70	-3.75	-2.95	-2.98	

23 EARNINGS QUALITY PANEL				live scores
MODEL	SCORE	ZONE	NOTE	
Piotroski F-Score	7 / 9	Strong		
Altman Z-Score	2.7	Grey zone	Grey	
Income quality	1.38	Cash-backed	OCF ÷ net income	
Beneish M-Score	-2.98	Non-manipulator	vs -2.22 threshold	

24 DUPONT & GROWTH QUALITY				live analysis engine
DUPONT DECOMPOSITION (TTM)		VALUE	GROWTH QUALITY (LIVE)	VALUE
Tax burden		0.78	Revenue stability	0.94
Interest burden		0.91	Earnings stability	0.17
Operating margin		26.6%	Earnings persistence	0.50
Asset turnover		0.54×	Revenue CAGR 3y	2.9%
Financial leverage		4.59×	EPS CAGR 3y	6.2%
= ROE		47%	FCF CAGR 3y	2.2%


THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

SHAREHOLDER RETURN PROFILE live

BUYBACK YIELD 0.08%	DIVIDEND YIELD 4.22%	TOTAL SHAREHOLDER RETURN 4.43% cash yield	SBC / REVENUE 1.1% dilution pressure
-------------------------------	--------------------------------	--	---

25 MULTIPLE HISTORY — FY SNAPSHOTS + TTM live ratio engine



26 PEER COMPARISON live peer engine

COMPANY	MKT CAP	P/E	ROE	NET MARGIN	REV GROWTH	PIOTROSKI	1-YR RET
PFE	\$168.6B	39.1	5%	-1.6%	-0.2%	7/9	+24.2%
GILD	\$193.7B	-60.1	-21%	—	+5.5%	5/9	+33.4%
AMGN	\$233.8B	26.7	91%	23.6%	+9.2%	8/9	+50.3%
AZN	\$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
NVS	\$286.3B	22.9	31%	22.7%	+0.8%	5/9	—
MRK	\$360.1B	115.8	7%	-8.0%	+4.5%	4/9	—
BIIB	\$34.4B	41.0	5%	3.6%	-0.5%	3/9	—
ABBV	\$504.4B	80.4	-206%	21.3%	+10.4%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

27 ANALYST CONSENSUS & ESTIMATES live consensus

Hold

42 Analysts



MEAN TARGET (QTR) \$65.54 13 targets	TARGET VS. PRICE +9.7% last-quarter mean	NEXT REPORT 2026-10-29 street \$1.09	
---	---	---	--

CONSENSUS ESTIMATES	REVENUE MEAN	HIGH / LOW	EPS MEAN	HIGH / LOW	# EPS EST.
FY2026	\$49.89B	\$50.15B / \$49.15B	\$6.32	\$6.65 / \$5.97	17
FY2027	\$48.50B	\$49.92B / \$47.41B	\$6.62	\$7.42 / \$6.12	17
FY2028	\$41.00B	\$44.73B / \$36.34B	\$5.41	\$6.67 / \$3.84	9

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

28 STREET TARGETS & THIRD-PARTY RATING

live targets + composite

Street Price Target — Trajectory

WINDOW	AVG TARGET	VS. PRICE	# TARGETS
Last Month	\$58.40	-2.3%	5
Last Quarter	\$65.54	+9.7%	13
Last Year	\$62.63	+4.8%	30
All Time	\$65.02	+8.8%	59

Rolling mean of published targets vs. last close \$59.75. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A-

DCF5/5

ROE5/5

ROA5/5

DEBT/EQ1/5


P/E3/5

P/B2/5

Independent quant composite as of 2026-10-16; components scored 1-5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

29 PRICE PERFORMANCE — INDEXED, 12 MO

live prices · benchmark + sector + peer set



All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL CHART — 6-MONTH DAILY CANDLES, INDICATORS ON site chart, print edition



Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

MOVING AVERAGE RIBBON & TREND site technicals-tab chart, live indicator history



MOVING AVERAGE	VALUE	DISTANCE	% DISTANCE	SIGNAL
SMA 20	\$60.35	-0.60	-0.99%	Below
SMA 50	\$62.99	-3.24	-5.14%	Below
SMA 200	\$58.48	+1.27	+2.17%	Above
EMA 9	\$59.46	+0.29	+0.49%	Above
EMA 21	\$60.43	-0.68	-1.13%	Below
EMA 50	\$61.37	-1.62	-2.64%	Below
EMA 200	\$58.01	+1.74	+3.00%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

30 TECHNICAL POWER SCORE

EDGE · site engine · 34/100 composite

TECHNICAL VERDICT

BEARISH

Power Score -33

7 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%

Momentum 25%

Volume 20%

Volatility 10%

Patterns 15%

33

40


31

0

50

BEARISH — BUT WHICH WAY IS IT TRENDING?

vote share recomputed weekly, 13 weeks




INDICATOR VOTE GRID

7 bull / 15 bear

● Price vs SMA 20	\$60.35	● Price vs SMA 50	\$62.99	● Price vs SMA 200	\$58.48
● EMA 9/21 Cross	59.5/60.4	● SMA 50/200	Golden	● ADX Direction	ADX 20
● Supertrend	\$62	● Parabolic SAR	\$56	● SMA Slope	-0.130
● RSI	45.5	● Stochastic K/D	51/36	● StochRSI K/D	81/52
● Williams %R	-51	● CCI	-9	● TSI vs Signal	-19.7
● CMO	-9.0	● ROC	-2.29%	● OBV Signal	Distrib
● Chaikin MF	-0.120	● MFI	33	● Force Index	-2M
● Elder Ray Bull	1.00				

INDICATOR GAUGES

site technicals-tab style



31 KEY LEVELS & VOLATILITY

live indicator table

LEVEL	VALUE	LEVEL	VALUE
Pivot / R1 / R2	\$61.07 / \$61.75 / \$62.93	S1 / S2	\$59.89 / \$59.21
Bollinger (20,2)	\$57.16 - \$63.54	Squeeze	Off
52-wk range	\$40.71 - \$67.94	Off 52-wk high	-12.1%
ATR (14)	\$1.77 (3.0%)	Historical vol	30.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

32 SEASONALITY — 20-YEAR AVERAGES

live model · win rates shown

-2.0% Jan 45%	+0.9% Feb 60%	+2.3% Mar 62%	-1.6% Apr 45%	-0.2% May 35%	+1.0% Jun 60%	+0.2% Jul 45%	-1.1% Aug 65%	+1.4% Sep 65%	+1.3% Oct 45%	+2.2% Nov 70%	+2.8% Dec 70%
---------------------	---------------------	---------------------	---------------------	---------------------	---------------------	---------------------	---------------------	---------------------	---------------------	---------------------	---------------------

Sample: 20 years — treat short histories as suggestive, not statistical.

33 RISK INDICATORS

computed from live price history

COMPUTED FROM LIVE WEEKLY PRICES	BMY	S&P 500
Weekly volatility (σ , 1y)	3.06%	1.83%
Best / worst week (1y)	+7.1% / -7.6%	—
Max drawdown (5y, monthly)	-42.0%	—
1-week VaR (95%)	-5.6%	—
Beta (5y)	0.23	1.00

34 EQUITY WEATHER & MARKET REGIME

EDGE · live weather engine

BMJ EQUITY WEATHER (LIVE)

RAINY · -35

Trend

Momentum

Volume

Volatility

Breadth

-31

-9

-55

-60

-30

MARKET REGIME (2026-10-16)

NEUTRAL

VIX

DOW THEORY

SPY / QQQ TSI

SECTOR STRENGTH

19.99

Confirmed Bearish


7.2 / 4.7

46/100

Normal

trend strength

breadth average



THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

36 WEATHER - COMPANY VS INDUSTRY, SECTOR, UNIVERSE

EDGE · live weather engine · Rainy

OVERALL -34.6 -25.0 vs industry	TREND -30.5 -26.4 vs industry	MOMENTUM -9.5 -19.3 vs industry	VOLUME -55.0 -71.6 vs industry
--	--	--	---

READING	BMY	DRUG MANUFACTURERS - GENERAL N=150	HEALTHCARE N=5,272	ALL US SYMBOLS N=70,435
Overall	-34.6	-9.5	-24.0	-20.5
Trend	-30.5	-4.1	-25.6	-21.3
Momentum	-9.5	+9.9	-28.5	-15.8
Volume	-55.0	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

37 EXECUTIVE COMPENSATION

live proxy data · FY2025

EXECUTIVE	TOTAL COMP	STRUCTURE
Christopher S. Boerner, Ph.D. Board Chair an	\$21.9M	91% equity+incentive
Samit Hirawat , M.D. Former EVP, Chief Medic	\$10.3M	65% equity+incentive
Cristian Massacesi , M.D. EVP, Chief Medical	\$10.1M	85% equity+incentive
Adam Lenkowsky EVP, Chief Commercialization	\$9.3M	85% equity+incentive
David V. Elkins EVP and Chief Financial Offi	\$9.2M	85% equity+incentive

38 ESG ASSESSMENT

live disclosure-derived scores

PILLAR (LIVE DISCLOSURE SCORES)	SCORE
Environmental	74
Social	65
Governance	71
Composite ESG	70



39 METHODOLOGY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

40 DISCLOSURES

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

41 DATA PROVENANCE FOR THIS REPORT			sources · coverage · method
DATA DOMAIN	SOURCE	COVERAGE FOR THIS REPORT	
Price & volume	market_db.historical_prices	52 rows	
Fundamentals	income_statements_annual	6 rows · 2020 to 2025	
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-07-30	
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31	
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	123 rows · 1995 to 2026	
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-01 to 2026-10-02	
Proposed sales (Form 144)	edgar/form144	not present for this symbol	
Beneficial ownership (13D/G)	edgar/13dg	not present for this symbol	
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15	
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31	
ETF & fund holding	etf_holdings_changelog (30d)	1 record	
Peer set	stock_peers_dynamic	8 rows	
Industry medians	industry_medians	1 record	
Congressional trades	congress_db (House + Senate)	1 record	
ESG	fact/esg_disclosures	1 record	

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.